November 17, 2026 · American heart journal · DOI: 10.1016/j.ahj.2026.107657

Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated with percutaneous coronary intervention. -insights from the SWEDEHEART registry.

Listen to this summary

This SWEDEHEART registry study examined how antithrombotic prescribing changed over 2010-2022 in patients with atrial fibrillation and acute coronary syndrome undergoing PCI, and whether treatment strategies were linked to outcomes. Among 15,358 patients, oral anticoagulation use rose from 27% in 2010 to 82% in 2021, and both vitamin K antagonist-based and DOAC-based strategies were associated with lower rates of MACE and NACE compared with platelet inhibition alone, with no significant difference between the two anticoagulant strategies. Because the analysis is observational, these associations may be affected by residual confounding.

Mikolaj Skibniewski, Gorav Batra, Emmanouil Charitakis, Magnus Janzon, Lars O Karlsson, Moman A Mohammad, Sammy Zwackman, Dimitrios Venetsanos, Joakim Alfredsson

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play